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Sparse-matrix sampling using commercially available crystallization
screen kits has become the most popular way of determining the
preliminary crystallization conditions for macromolecules. In this
study, the ef®ciency of three commercial screening kits, Crystal
Screen and Crystal Screen 2 (Hampton Research), Wizard Screens I
and II (Emerald BioStructures) and Personal Structure Screens 1 and
2 (Molecular Dimensions), has been compared using a set of 19
diverse proteins. 18 proteins yielded crystals using at least one
crystallization screen. Surprisingly, Crystal Screens and Personal
Structure Screens showed dramatically different results, although
most of the crystallization formulations are identical as listed by the
manufacturers. Higher molecular weight polyethylene glycols and
mixed precipitants were found to be the most effective precipitants in
this study.
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1. Introduction
Crystallization remains one of the major
bottlenecks in macromolecular structure
determination by X-ray crystallography. The
search for conditions suitable for crystal
growth remains largely empirical, particularly
screening for initial crystallization conditions.
Once initial crystals have been obtained, the
conditions can usually be optimized by a more
systematic approach.
Because crystallization is affected by many
variables and the amount of protein is usually
limited, sampling of the multidimensional
condition space can be challenging. Various
approaches have been proposed for this task.
While sampling methods such as the incom-
plete factorial approach (Carter & Carter,
1979), orthogonal arrays (Kingston et al., 1994)
and reverse screening (Stura et al., 1994) offer
statistically superior sampling of various
parameters or a more methodical route to
obtaining preliminary crystals, the method of
sparse-matrix screening has arguably become
the most popular approach for initial crystal-
lization screening. In an early application of
sparse-matrix sampling, a set of 50 crystal-
lization solutions was proposed based on
known or published crystallization conditions
for various proteins (Jancarik & Kim, 1991).
Many variations of sparse-matrix screens have
subsequently been developed in various
laboratories and the popularity of such screens
has increased through the availability of
commercial kits (e.g. Crystal Screen, Hampton
Research). The sparse-matrix approach was
originally suggested to be well suited to auto-
mation (Jancarik & Kim, 1991) and, accord-
ingly, this approach has been adopted by
structural genomics initiatives (Burley, 2000).
Here, we posed the question whether three
popular commercial screens (Crystal Screen
and Crystal Screen 2, Hampton Research;
Wizard Screens I and II, Emerald Bio-
Structures; Personal Structure Screens 1 and 2,
Molecular Dimensions) are similarly effective
in crystallizing a set of 19 diverse proteins.
Surprisingly, we found that the Hampton
Research Crystal Screens and Molecular
Dimensions Personal Structure Screens
yielded quite different results, although most
of the formulations are identical as listed by
the manufacturers. Our study shows some
trends in the ef®ciency of individual crystal-
lization components in the crystallization of
proteins and will help in formulating even
more ef®cient crystallization screens.
2. Experimental methods
The following proteins were used without
further puri®cation: equine myoglobin, hen
egg-white lysozyme, bovine catalase, rabbit
phosphorylase B, porcine pepsin, bovine
-lactalbumin, bovine trypsin, human haemo-
globin, Bacillus licheniformis subtilisin Carls-
berg, bovine ribonuclease A, porcine elastase
(all obtained from Sigma±Aldrich), Tricho-
derma longibrachiatum xylanase and Strepto-
myces rubiginosus glucose isomerase (both
obtained from Hampton Research). Porcine
ribonuclease inhibitor (Kobe & Deisenhofer,
1993), mouse importin- (Teh et al., 1999),
feline immunode®ciency virus gp36 (residues
652±784)±maltose-binding protein (MBP)
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chimera (Y. M. Qi, P. Poumbourios & B.
Kobe, unpublished work), Saccharo-
myces cerevisiae Dun1p (residues 19±159)
(Hammet et al., 2000), human Chk2
(residues 214±543)±maltose-binding protein
chimera (H. T. Lee & B. Kobe, unpublished
work) and Escherichia coli DsbG (B. Heras,
S. Raina & J. L. Martin, unpublished work)
were puri®ed in our laboratories (Table 1).
The proteins were used at a concentration of
10 mg mlÿ1 (dissolved or dialysed in 25 mM
Tris±HCl pH 7.0), except for ribonuclease
inhibitor (27 mg mlÿ1 in 20 mM HEPES pH
7.0), importin- [11 mg mlÿ1 in 20 mM Tris±
HCl pH 8.0, 100 mM NaCl, 2 mM dithio-
threitol (DTT)], gp36±MBP (14 mg mlÿ1 in
100 mM Tris±HCl pH 6.5, 300 mM NaCl),
Dun1p (12 mg mlÿ1 in 20 mM imidazole pH
7.0 and 15 mM -mercaptoethanol), Chk2±
MBP (8.6 mg mlÿ1 in 50 mM Tris pH 7.5,
0.5 M NaCl, 10% glycerol, 5 mM DTT) and
DsbG (10 mg mlÿ1 in 25 mM HEPES pH
6.7, 150 mM NaCl, 5 mM DTT). Trypsin and
subtilisin were inhibited with 4.2 and 3.7 mM
Pefabloc SC inhibitor (Roche), respectively.
The hanging-drop vapour-diffusion
method was used for crystallization. 1 ml of
protein solution was combined with 1 ml of
reservoir solution on the sticky side of 3M
PCR tape (using an eight-channel pipette),
the tape was inverted over a Falcon ¯at-
bottom 96-well plate containing 100 ml of
reservoir solution per well and the plate was
incubated at 289 K. For each protein, three
plates were set up, each plate containing 96
conditions corresponding to Crystal Screen
(CS1) and Crystal Screen 2 (CS2) (Hampton
Research; both screens are referred to as
CS), Wizard Screens I (WS1) and II (WS2)
(Emerald BioStructures; both screens are
referred to as WS) and Personal Structure
Screens 1 (PSS1) and 2 (PSS2) (Molecular
Dimensions; both screens are referred to as
PSS), respectively (owing to a limited
amount of protein, PSS was not completed
for ribonuclease inhibitor). Formulation 1 in
CS2, WS2 and PSS2 is numbered 49 in this
setup. To accommodate all formulations on a
96-well plate, conditions 49 and 50 of CS1
and PSS1 were omitted. Conditions 1 and 2
from PSS1 were substituted by conditions 49
and 50 from PSS2, respectively. To mimic a
typical crystallization screening experiment
using a novel protein, one drop was set up
per condition and protein; the reader should
note that this poses limitations on the
statistical validity of any conclusion drawn.
All the formulations are listed in Supple-
mentary Table S11.
The drops were inspected using a stereo
dissecting microscope (Leica MZ75) imme-
diately after set-up and after one week; the
®nal results were compiled after 1±2 months.
Needles, plates and three-dimensional crys-
tals were considered as successful crystal-
lizations, regardless of the size of the
crystals. The diffraction quality of the crys-
tals was not assessed. Because not all crys-
tals were tested for protein content, it is
possible (although unlikely) that some
crystals considered to be protein crystals did
not contain protein. The formulations
resulting in successful crystallizations are
listed in Supplementary Table S2.
The pH of the formulations in CS and PSS
was measured using an Ionode pH meter
(TPS, Brisbane, Australia) at 289 K
(Supplementary Table S3).
3. Results and discussion
The proteins we used in our test set were
chosen to represent a diverse set of proteins
from a diverse set of organisms (ranging
from bacteria and viruses to humans), with
diverse molecular weights and pI values and
with diverse functions (ranging from
enzymes through proteins involved in
protein±protein interactions and cofactor-
binding proteins to recombinant fusion
proteins) (Table 1). Most of these proteins
have previously been shown to be crystal-
lizable under some set of conditions. In our
analysis, we obtained crystals for 18 out of 19
proteins using at least one of the screen
conditions; this observation highlights the
high ef®ciency of the commercial screens in
obtaining preliminary crystals (Supplemen-
tary Fig. S1). The study also showed that the
crystallization technique using vapour
diffusion with 96-well plates and the place-
ment of drops directly onto the tape, a
technique amenable to high-throughput
crystallization, is an effective crystallization
method.
The highest success rate in crystallizing
our set of proteins was achieved with PSS
(17 out of 18 proteins; for CS and WS, 13 out
of 19 proteins produced crystals). Ten
proteins crystallized in all three screens.
Many proteins crystallized using numerous
different formulations, with the highest
number recorded for glucose isomerase (63
conditions; Supplementary Table S2). The
only protein that failed to crystallize was
haemoglobin; successful crystallizations
have previously been reported for this
protein (Perutz, 1968) and we conclude
that its crystallization may require
higher concentrations of protein, different
temperatures or other conditions not
sampled in this study [a standard concen-
tration of 10 mg mlÿ1 (Jancarik & Kim,
1991) was used for most proteins in this
study].
The most successful formulation overall
was No. 14 from CS [28% poly-
ethyleneglycol (PEG) 400, 100 mM HEPES
pH 7.5 and 200 mM calcium chloride], which
produced crystals for ten (53%) of the
proteins (Fig. 1). Another formulation
produced crystals for eight different
proteins, two formulations produced crystals
for seven proteins and three formulations
produced crystals for six proteins (Fig. 1).
The most effective formulations in CS are
Table 1
Proteins used, sources, various properties and the outcomes of crystallization in the three screens (WS, Wizard
Screens I and II; CS, Crystal Screen and Crystal Screen 2; PSS, Personal Structure Screens 1 and 2).
Protein Biological source
Calculated
pI²
Theoretical molecular
mass (kDa) WS CS PSS
Myoglobin Horse skeletal muscle 7.4 17.0 Yes Yes
Lysozyme Hen egg white 9.4 15.2 Yes Yes Yes
Catalase Bovine liver 6.4 57.6 Yes Yes Yes
Xylanase T. longibrachiatum 9.0 20.7 Yes Yes Yes
Phosphorylase B Rabbit muscle 6.8 97.2 Yes Yes Yes
Pepsin Porcine gastric mucosa 4.0 41.4 Yes
Chk2±MBP Human 5.6 80.1 Yes
Glucose isomerase S. rubiginosus 3.0 43.2 Yes Yes Yes
-Lactalbumin Bovine liver 4.9 16.2 Yes Yes Yes
Trypsin Bovine pancreas 4.7 26.3 Yes Yes Yes
Haemoglobin Human 7.8 62.0
Subtilisin Carlsberg B. licheniformis 6.6 27.2 Yes Yes
Ribonuclease A Bovine pancreas 8.9 16.4 Yes Yes Yes
Ribonuclease inhibitor Porcine 4.8 49.0 Yes Yes Ð³
Elastase Porcine pancreas 8.4 28.8 Yes Yes Yes
DsbG E. coli 7.4 27.0 Yes Yes Yes
Dun1-FHA S. cerevisiae 8.8 16.9 Yes
Importin- Mouse 5.8 63.6 Yes Yes
gp36±MBP Feline immunode®ciency virus 6.5 56.4 Yes Yes
² The pI was calculated using the ExPASy Moelcular Biology Server (http://www.expasy.ch) (Bjellqvist et al., 1993). ³ Not
analysed owing to limited amount of protein.
1 Supplementary material has been deposited in
the IUCr electronic archive (Reference: gr2328).
Details for accessing these data are described at
the back of the journal.
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consistent with a histogram of successful
crystallizations presented in the Hampton
Research Catalogue. Two proteins were
crystallized uniquely with only one condi-
tion. No crystals were obtained with 31, 40
and 44% of the formulations in PSS, CS and
WS, respectively.
One unexpected result that emerged from
this study was the difference in ef®ciency
between CS and PSS. Most crystallization
formulations in these two screens are iden-
tical as listed by the manufacturers. Figs. 1(d)
and 1(e) show a comparison of the two
screens after we matched the conditions (the
order of the formulations is different in the
two screens; Supplementary Table S3). In 38
cases, the solutions in PSS were more
successful in producing crystals than CS,
while the opposite was the case for 26
formulations. For example, the PSS equiva-
lent of the most successful formulation in CS
(No. 14, ten successful crystallizations)
produced only one successful crystallization;
conversely, the CS equivalent of the most
successful formulation in PSS (No. 46, eight
successful crystallizations) produced only
one successful crystallization. Crystal
nucleation is a chance event and some ¯uc-
tuation in the results is unavoidable;
however, nucleation in virtually all drops
producing crystals was frequent enough to
prevent large ¯uctuations. Some of the
differences could therefore result from the
source of the chemicals and the procedures
used by the companies in preparing the
formulations. For example, Hampton
Research prepare the buffers by adjusting
the pH with hydrochloric acid or sodium
hydroxide, whereas Molecular Dimensions
use glacial acetic acid to adjust the pH
(personal communication). 22 matched
formulations had pH values which differed
by more than half a pH unit between the
two screens, with the highest discrepancy
reaching almost 5 pH units (Supplementary
Table S3). Many of the discrepancies in pH
correspond to formulations that use no
buffer or speci®c chemicals such as Jeffa-
mine M-600. The pH differences and similar
but non-identical formulations explain some
but not all of the cases where only one
screen produced crystals.
We also analysed the results to deduce the
effects of individual components of the
crystallization formulations. Because this is
not a systematic analysis of individual
components and other components present
may modulate any effects of an individual
component, inferences must be made
cautiously. The most effective precipitant
class corresponded to polymers (7.8%
success over all formulations), compared
with salts (5.0%), non-volatile and volatile
organic solvents (5.5 and 3.2%, respectively)
and other precipitants (7.6%) (Supplemen-
tary Table S3 and Fig. S2). The success of the
Figure 1
(a) Histogram showing the number of successful crystallizations using WS formulations. Needles, yellow;
rods, orange; three-dimensional crystals, black. (b) The results of CS, shown as in Fig. 1(a). (c) The results
of PSS, shown as in Fig. 1(a). (d) Comparison of CS and PSS. Equivalent formulations were matched and
the number of successful crystallizations is shown for each equivalent condition side by side (CS, black;
PSS, white; see Supplementary Table S3 for the matched conditions). The numbers correspond to the
order of formulations in CS. CS conditions 50, 64, 67 and 94 are similar but not identical in PSS. CS
conditions 1 and 10 do not have a match in PSS in our setup and the number of successful crystallizations
is therefore not shown in the histogram for these conditions (i.e. the numbers are set to zero). (e)
Comparison of CS and PSS, shown as a Venn diagram. Only identical conditions were considered in the
comparison. CS, number of crystallizations unique to CS; PSS, number of crystallizations unique to PSS;
cross-section, number of crystallizations in both CS and PSS using the identical formulations.
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`other' precipitant class entirely arises from
the `combined precipitants', most of which
contain at least one polymer precipitant.
The precipitants imidazole, urea, poly-
ethyleneimine and polyvinylpyrolidone
yielded no crystals, while Jeffamine M-600
produced only one successful crystallization
(however, these precipitants are poorly
represented among the formulations). No
signi®cant trends are observed among indi-
vidual salts (see also a recent study by
McPherson, 2001) and organic solvents; on
the other hand, there is a clear trend of
increasing success rates with increasing PEG
molecular weights, showing maxima at PEG
10 000 and PEG MME 5000 (jointly the
most effective precipitants, with a success
rate of 18.9%; Fig. 2). The results suggest
that there may be an optimal molecular
weight of PEG that balances the effects of
lowering the dielectric constant of water and
reducing protein solubility and of inducing
crystal growth. Of the salts, the most
successful precipitant was lithium sulfate
(success rate 10.8%) and of the organic
solvents, surprisingly, it was dioxane (success
rate 8.1%). Three combined precipitants
had a success rate of 13.5%; two of these
contained PEG 4000 and 2-propanol, while
the other was a combination of ammonium
sulfate and PEG 400. These results suggest
that PEGs and the less well known PEG
monomethylethers (MMEs; Brzozowski &
Tolley, 1994) are the most effective precipi-
tants and that it is also very bene®cial to
explore the combined precipitants, perhaps
through the effects of `hard' and `soft'
precipitants (Huang et al., 1999).
Successful crystallization as a function of
pH shows two maxima at pH 5.5 and 8.0
(Supplementary Fig. S3). The success rate
decreases between these two points, with a
minimum at pH 6.2. Owing to a non-random
association of the pH values with particular
crystallization components and the uneven
sampling distribution of the pH values, the
signi®cance of this observation is unclear;
however, it is in line with previous obser-
vations (McPherson, 1999). There does not
appear to be any correlation between crys-
tallization success and the calculated pI
values of the proteins (Table 1).
Another way to assess the effects of
different components is to analyse the least
successful formulations. For example, heavy
irregular precipitation could point to
conditions where proteins (at the concen-
trations used here) were either dramatically
above the solubility limit or were severely
destabilized. The analysis shows that most
conditions frequently inducing heavy preci-
pitation contain zinc acetate or another
divalent ion-containing salt, have a pH of 4.6
or lower or contain PEG (with molecular
weight 4000 or higher) at a concentration of
30%. These observations suggest that low
pH values and divalent ions may be detri-
mental to the stability of many proteins and
that concentrations of 30% of PEGs with
molecular weights of 4000 may cause the
proteins to substantially exceed the solubi-
lity limit.
We consider the observed trends are
likely to be representative of proteins in
general, despite the limited number of
proteins used in this study. However, more
comprehensive information should soon
emerge from analyses of the large numbers
of crystallization experiments performed by
structural genomics initiatives.
4. Conclusions
All three commercially available screens
used in our analysis were shown to be highly
successful in yielding preliminary crystal-
lization conditions for the diverse proteins in
our test set. Certain formulations show very
high success rates and our analysis should
help to formulate new sparse-matrix screens
that are even more ef®cient than those
presently available. The unexpected differ-
ence in the ef®ciency of CS and PSS
emphasizes the importance of the prepara-
tion, purity and quality of crystallization
components in inducing crystal growth and
the delicacy of protein crystallization. It also
suggests that it is worthwhile setting up both
screens, despite the fact that most formula-
tions are identical as listed by the manu-
facturers. The success rates of individual
components are consistent with trends
observed in other studies and suggest higher
molecular-weight PEGs and PEG MMEs to
be particularly useful crystallization agents.
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Relative success (needles, plates and three-dimensional crystals were considered to be successful crystallizations)
for various PEGs, calculated over all the screens and all 19 proteins (5376 conditions).
